Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
Trials. 2022 Jan 5;23(1):13. doi: 10.1186/s13063-021-05669-9.
Trials. 2022.
PMID: 34986897
Free PMC article.
Clinical Trial.